WebBased in Bedford, Massachusetts. Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies for eye diseases and … WebMar 6, 2024 · Top-Line Data from Phase 2 Clinical Trial of OTX-TIC (travoprost intracameral implant) for the Treatment of Patients with Primary Open-Angle Glaucoma or Ocular Hypertension Expected in Q4 2024...
Ocular Therapeutix™ Reports Fourth Quarter and Year-End 2024 …
WebInterim Topline Data from the Phase 1 Clinical Trial of OTX-TIC in Patients with Glaucoma. Learn More About Phase 1 Clinical Trial. ... Ocular Therapeutix, Inc. maintains … Ocular Therapeutix makes no representations or warranties with … Pipeline - Ocular Therapeutix DEXTENZA provides an opportunity for physicians to alleviate their patients of … Careers - Ocular Therapeutix About Wet Age-Related Macular Degeneration. Age-related macular … Data on file 018. Ocular Therapeutix, Inc. 6. Messmer EM. Dtsch Arztebl Int. … ReSure Sealant is indicated for intraoperative management of clear … Information Request - Ocular Therapeutix At Ocular Therapeutix, the company values are embodied in the work we do and … WebJan 23, 2024 · Item 8.01 Other Events. On January 23, 2024, Ocular Therapeutix, Inc. (the “Company”) announced that it had resubmitted a new drug application (an “NDA”) to the U.S. Food and Drug Administration (the “FDA”) for DEXTENZA™ (dexamethasone insert) 0.4 mg for the treatment of ocular pain occurring after ophthalmic surgery. is the first name the family name
SEC.gov HOME
WebOct 19, 2024 · 2.1 General Dosing Information - DEXTENZA is an ophthalmic insert that is inserted in the lower lacrimal punctum into the canaliculus. A single DEXTENZA insert releases a 0.4 mg dose of ... 3 DOSAGE FORMS AND STRENGTHS Ophthalmic insert: fluorescent yellow, 3 mm cylindrical-shaped insert containing dexamethasone, 0.4 mg. 4 … WebNov 2, 2024 · BEDFORD - Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced a license agreement and a collaboration with AffaMed Therapeutics for the … WebApr 14, 2024 · BEDFORD, Mass., April 14, 2024--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for ... iguana wana pleasant prairie wi